Regenesance, developing novel treatments
for immune mediated and neurodegenerative disorders

  • bomen-home

First Therapeutic Product Focus

Regenesance is developing a line of products based on proprietary monoclonal antibodies to inhibit formation of the Membrane Attack Complex (MAC) part of the complement pathway.

Regenesance is focused on developing treatments for the orphan drug indications...

About us

Regenesance has developed the monoclonal antibody Regenemabâ„¢ for the treatment of neurodegenerative and immune mediated disorders, first target indication is PNH.


BioCapital 2015

Regenesance presenting on BioCapital Europe. March 26, 2015.

EPIC Biotech, October 2015

Regenesance presenting on EPIC Biotech. October 8, 2015.

June 2014

Regenesance antibody fully characterized and ready for production.